About Encorafinib
Class: | BRAF kinase inhibitor
Use: | Encorafenib (BRAFTOVI) is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test, in combination with binimetinib. It is also used in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
Adult dose: | For melanoma: 450 mg orally
Drug Class
BRAF kinase inhibitor
Uses & Indications
Encorafenib (BRAFTOVI) is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test, in combination with binimetinib. It is also used in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
Storage Requirements
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep the bottle tightly closed.
Manufacturer & Packaging
Manufacturer: Pierre Fabre Australia Pty Ltd, Australia
Package Size
42's
Price & Supplier
Price in UAE: AED 7507.92
Dosage Information
Adult Dose
For melanoma: 450 mg orally once daily in combination with binimetinib. For colorectal cancer: 300 mg orally once daily in combination with cetuximab.
Pediatric Dose
Safety and efficacy in pediatric patients have not been established.
Side Effects
Common side effects include fatigue, nausea, diarrhea, vomiting, abdominal pain, arthralgia, rash, and hyperkeratosis.
Contraindications & Precautions
There are no specific contraindications listed, but it should not be used in patients with known hypersensitivity to encorafenib or any of its components.
Important Warnings
Serious risks include new primary malignancies, hemorrhage, uveitis, QT prolongation, and hepatotoxicity. Regular monitoring for these conditions is recommended. Use with caution in patients with a history of cardiovascular disease.
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.